Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 5,231 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Heart Failure, Type 2 Diabetes Mellitus
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 94
States / cities: Alexander City, Alabama • Cottonwood, Arizona • Little Rock, Arkansas + 83 more

Conditions: Healthy
Interventions: JNJ-39439335 10 mg, JNJ-39439335 25 mg, JNJ-39439335 50 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Cytomegalovirus Infections
Interventions: Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline solution); Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 18
States / cities: Anaheim, California • Long Beach, California • Los Angeles, California + 15 more

Conditions: Migraine
Interventions: Lu AG09222, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 874 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Hoover, Alabama • Carlsbad, California • Fullerton, California + 24 more

Conditions: Hypercholesterolemia
Interventions: Evinacumab, Matching placebo, Background Lipid Modifying Therapy (LMT); Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 23
States / cities: Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Modafinil; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 23
States / cities: Little Rock, Arkansas • Irvine, California • San Francisco, California + 20 more

Conditions: Alzheimers Disease
Interventions: CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum; Biological · Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 78
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more

Conditions: Schizophrenia
Interventions: Lumateperone 42 mg, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 21
States / cities: Little Rock, Arkansas • Bellflower, California • Cerritos, California + 18 more

Conditions: Asthma
Interventions: tiotropium-bromide, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Year to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more

Conditions: Spinal Cord Injuries, Neuropathic Pain
Interventions: brivaracetam, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Narcolepsy
Interventions: SUVN-G3031, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 30 more

Conditions: Lumbar Spine Degeneration
Interventions: saline 0.9%, Liposomal bupivacaine; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Rheumatoid Arthritis
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 12
States / cities: Anniston, Alabama • Birmingham, Alabama • Peoria, Arizona + 8 more

Conditions: Obesity
Interventions: intravenous acetaminophen, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Ileus
Interventions: Alvimopam, 300 mg Polyethylene; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: American Fork, Utah • Cedar City, Utah • Logan, Utah + 6 more

Conditions: Charcot-Marie-Tooth Disease Type 1A
Interventions: PXT3003 dose 1, PXT3003 dose 2, placebo; Drug
Lead sponsor: Pharnext S.C.A.; Other
Eligibility: 16 Years to 65 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Los Angeles, California • New Britain, Connecticut • Gainesville, Florida + 8 more

Conditions: Plantar Fascitis
Interventions: Ultrasound, manual therapy and exercise; Other
Lead sponsor: The Sage Colleges; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Troy, New York

Conditions: Pseudofolliculitis Barbae
Interventions: Eflornithine Topical, Placebo Eflornithine Topical; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Idiopathic Constipation
Interventions: Plecanatide, Matching placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 36
States / cities: Foley, Alabama • Jonesboro, Arkansas • Cerritos, California + 33 more

Conditions: Renal Insufficiency, Chronic, Hypertension
Interventions: Chlorthalidone, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cardiovascular Diseases
Interventions: Lifestyle behavior interventon grop, Placebo Comparator: Control group; Behavioral · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 35 Years to 64 Years · Female only
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Fluid Retention, Sodium Retention, Heat Stress, Dehydration (Physiology), Renal Injury, Electrolyte and Fluid Balance Conditions
Interventions: PR Lotion - AMP Human Performance, Placebo Lotion, AminoVital - Rapid Recovery, Placebo Supplement; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Joint Disease
Interventions: HOE140 Icatibant; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 41
States / cities: Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more

Search by objective public record fields.

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

A Randomized Trial of Exparel vs Saline in Opioid Reduction of Pain Management Following Lumbar Spine Surgeries.

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

Prospective, Double Blind, Placebo Control, Bariatric IV Ace

Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)

The Effectiveness of Ultrasound Treatment in the Management of Plantar Fasciitis

Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

Chlorthalidone in Chronic Kidney Disease

Healthy Lifestyle Behavior Intervention for Latino Women

The Effect of AMP Human Sodium Bicarbonate Lotion on Dehydrated Heat Stress

Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)